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INTRODUCTION
Contemporary thought on genetic research of complex traits in humans is that large scale 48 genome-wide association studies (GWAS) are required to identify reproducible single nucleotide 49 polymorphism (SNP) associations that can lead to insights into biological systems that underpin 50 a particular phenotype. The agnostic nature of GWAS, i.e., all SNPs being tested without bias, is 51 a strength that allows for the identification of previously unrecognized biological underpinnings. 52 animal's drinking water, and nicotine-induced conditioned place preference (see Table 1 ; no 139 studies involving Drosophila melanogaster were identified which was most likely due to the fact 140 that nicotine is a natural insecticide). Priority was given to weighted gene co-expression network 141 analysis (WGCNA) studies to minimize inflation of the Type I error rate typically seen in QTL 142 studies. Next, we merged studies with multiple reported gene sets (i.e., either by region, up/down 143 regulated, or across time) to avoid inflating the replication threshold of individual genes. We 144 then identified orthologous genes using GeneWeaver's "Combine Gene sets" function which 145 merges multiple gene sets into a single matrix while accounting for orthology across species; 146 none of the identified studies were conducted in human samples. 13 Lastly, identified gene sets 147
were compared to the current human genome build (hg19) to localize relevant variants that were 148 conserved across species; 712 orthologous genes were identified. Given the lack of a proof of 149 principle for prospectively integrating model organism evidence in human studies we integrated 150 the limited evidence across studies, especially given the minimal overlap between gene sets 151 (Jaccard similarity ~0.00-0.01; supplemental Table S1 ). Of these genes, 201 were replicated 152 twice across GeneWeaver gene lists. For instance, ABL1 and GRIK2 were only observed in five 153 brain regions from the Wang et al. study, but not observed in other studies. Supplementary 154 Figure 1 provides a bipartite graph visualization of the 51 genes that were present in at least three 155 gene lists. When collapsing across study and removing duplicates, 21 genes were observed 156 across studies (see Supplementary Table S2 ). None of them overlapped across more than two 157 studies. The analyses described below focused on SNPs in and around the 712 orthologous genes 158 (GeneWeaver Gene Set ID: GS357552). 159 -------------------------------------Insert Figure 1 here -----------------------------------160 -------------------------------------Insert Table 1 here -----------------------------------162 163 Fold creation and power calculation for the UK Biobank tobacco consumption sample 164
Hypotheses were tested using multiple subsets (i.e., folds) of the UKB data for 165 computational efficiency and to demonstrate the robustness of the findings via replication as 166 each dataset contained unrelated individuals. Analyses focus on the reported number of 167 cigarettes by each participant (i.e., for prior and current smokers; nonsmokers were excluded). 168
We identified 139,043 individuals of European ancestry as identified by principal components 169 analysis and multidimensional scaling 16; 17 , who were no more related than second cousins and 170 who also provided smoking data. The number of folds were determined a priori in order to 171 maximize statistical power. The GCTA-GREML Power Calculator was used to estimate a priori 172 power for sample sizes that provided at least 70% power to detect SNP-heritability estimates as 173 small as one-third of 1% (0.333%). 18 Power was based on the previously reported SNP-174 heritability and observed variance of the off-diagonal elements (~6.68x10 -4 ) in each fold. 6 
175
Consequently, the total sample was divided into three approximately equal folds (n nic1 =41,263, 176 n nic2 =41,368, n nic3 =41,213), each of which was made constitutionally equivalent by randomly 177 sampling individuals from each quartile of the nicotine consumption distribution. 178
Genotype quality control 179
Analyses focused on raw and imputed genotypes obtained using the Affymetrix UK 180 BiLEVE Axiom and UK Biobank Axiom® arrays, which genotyped ~850,000 variants (details 181 available here: https://www.ukbiobank.ac.uk/scientists-3/genetic-data/). Quality control and 182 imputation (to over 90 million SNPs, indels, and large structural variants) was performed by a 183 collaborative group headed by the Wellcome Trust Centre for Human Genetics. Analyses focused on genotyped and imputed SNPs with good quality scores (r 2 > 0.3). PLINK (version 1.9) 185 was used to filter markers using the following criteria: genotyping rate >99%, minor allele 186 frequency > 0.01, Hardy-Weinberg equilibrium p-value > 0.0001, and missing genotype rate < 187 0.10. 19 188 189 Given evidence for the import of intergenic variants in complex traits/disease, we 191 partitioned the genetic variance of nicotine consumption into three regions-of-interest based on 192 the list of genes acquired from the GeneWeaver database. 20 As illustrated in Figure 2 , the "gene" 193 region was demarcated by the start and stop positions of each of the consumption genes. The 194 flanking "buffer" regions of the genome were set to encompass the base pairs directly up-/down-195 stream of the 5' and 3' ends of each gene, respectively. We considered six buffer lengths in order 196 to capture the effects of transcription factor (TF) binding sites whose exact position is unknown 197 (0 kilo-base pairs (kb), 5kb, 10kb, 25kb, 35kb, and 50kb). Following marker extraction, the 5' 198 and 3' variants for each buffer length were aggregated into a single buffer marker variant list for 199 a given length. In addition, we examined the effects of all unselected variants (referred to as 200 "other variants"), which belonged to regions of the genome that comprised SNP markers that 201 were not within the parameters specified for the gene or buffer regions defined by the 202 consumption gene set ( Table 2 provides a count of the number of SNPs assigned to each 203 component of the model). Consequently, the number of SNPs that comprised the "other variants" 204 category varied depending on the length of the buffer regions. 205
Regions

206
The relative contribution of variants within the gene, buffer, and 'all other' components 209 was evaluated under a polygenic model. Regions-of-Interest heritability mapping was achieved 210 using multiple genetic components in GREML analyses implemented in GCTA [version 1.92] 211 using the set of SNPs from each ROI to define the components of the model. 21; 22 Analyses 212 employed a set of three genetic relatedness matrices (GRMs) for a given fold. Variance 213 component ROI-G reflected variation across SNPs in the transcriptionally regulated gene set 214 depicted in Table 1 . ROI-Buffers, of varying lengths, was used to reflect the effect of loci around 215 the ROI-G. ROI-All_Others, reflected aggregate variant effects from the remainder of the 216 genome, given the corresponding size of ROI-G and ROI-Buffer. The significance of each 217 variance component was assessed using a likelihood ratio test while accounting for age and sex. 218
Population stratification effects were controlled using strict selection for individuals of European 219 Ancestry using genomic principal components and multidimensional scaling. 11 Enrichment (E) 220 values were calculated to determine whether the observed component-heritability estimates were 221 greater than what would be expected by chance given the observed total genetic variance and the 222 4.6 million SNPs used in the analysis (i.e., the variance explained we would expect via a random 223 selection of loci of the same size from the genome). As such, the statistical significance of an 224 enrichment was evaluated on the basis of whether the expected h 2 SNP fell within the 95% 225 confidence interval of the observed h 2 SNP (i.e., E > 1.96). 226
There was limited association between variance explained by ROI-G and buffer length 252 (model R 2 across folds ranging 0.003-0.09; see Figure 3 panel A). On the contrary, the variance 253 explained by SNPs in and around the genes of interest (i.e., ROI-Buffer) that were modeled using 254 buffers of various length (ROI-buffer-#Kb) increased over buffer size (model R 2 across folds 255 ranging 0.75-0.86; see Figure 3 panel B), whereas the variance explained decreased for All_Others as buffer size increased (model R 2 across folds ranging 0.73-0.81; see Figure 3 panel 257 C). This result is in line with the observation from previous work that variance explained is 258 proportional to DNA length 22 , consistent with a polygenic model. Notably, variance explained by 259 variants located around genes of interest were positively associated with buffer size, but the 260 enrichment decreased with buffer size (see Figure 4 ), suggesting that that the trait-associated 261 variants are more enriched near genes. 262
Genome-wide Association, Gene-based, and Gene set effects 266
Association analyses using all 139,043 smokers confirmed previously associated regions 267 identified in a larger meta-analysis that included these data. 6 We identified 594 signals that were 268 genomewide significant, and a larger set of 938 signals with q<0.05 (see supplementary Table S3  269 for complete summary statistics and Supplementary Figures S2 and S3 for the Manhattan and Q-270 Q plot, respectively). The top signals resided on chromosomes 15, 19, 8, 7, 4, 3, and 1 (see 271 Supplementary Figures S4 thru S7 for regional association plots for associations across nicotinic 272 acetylcholine receptor genes CHRNA4/A5/A6 and CYP2A6, respectively). Most of the 273 associated SNPs are functionally annotated as intronic, intergenic, and intronic non-coding RNA (see Supplementary Figure S8 ). Gene-based analyses identified 20 genes that surpassed the 275 Bonferroni significance threshold and 31 with q<0.05 (see Supplementary Table S4 and  276 Supplementary Figures S9 and S10 for the gene-based test Manhattan and Q-Q plots, 277 respectively). Of the gene-wide significant genes, four were differentially expressed across the 278 model organism experiments and this overlap was more than we would expect by chance, OR = 279 7.20, empirical p = 4.41E-3. Post-hoc examination of the test statistics (i.e., using 10,000 280 permutations of 500 gene sets from non-GeneWeaver genes) indicated that the majority of the 281 signals originated from genes largely captured by the a priori Mus musculus studies (two sample 282 t-test: t = 2.2813, df= 664.87, empirical p = 0.023; Supplementary Figure S11 ). Gene set 283 analyses, which focused on curated gene sets and GO term annotations from MsigDB, identified 284 745 significant gene sets (p<0.05), but only one gene set, REACTOME: Presynaptic Nicotinic 285 Acetylcholine Receptors (R-HSA-622323; https://reactome.org/PathwayBrowser/#/R-HSA-286 622323) survived multiple-testing correction (Bonferroni-corrected p = 2.5x10 -8 ). 287
288
DISCUSSION 289
We integrated genomic and bioinformatic analyses which provided a rapid approach for 290 filling the translational space between human and animal genetics research. Similar to other 291 genetic studies of drug use 26-28 , these findings indicated a neuro-epigenetic component to the 292 genetic inheritance of tobacco consumption, while also localizing genomic regions of interest. 293
By using a genetic sample of over 100,000 humans and meta-analyzing across three species from 294 seven gene expression studies, we found that approximately 4.2%-39.5% of the heritability for 295 the frequency of human tobacco use can be attributed to mRNA readout related to nicotine 296 exposure/consumption in the brain. Given that the observed neuro-molecular associations observed with tobacco/nicotine use were inferred via model systems, irrespective of prior GWAS 298 findings, it stands to reason that integrating knowledge across species will enhance genomic 299 discoveries related to tobacco use. Importantly, most cross-species findings appeared to be 300 buried under the conservative genome-wide significant threshold -demonstrating the strength of 301 our approach, which incorporates significant and non-significant sources of genomic variations a 302 priori and helps accommodate the numerous (relevant) genes with small effect sizes riddled 303 across the human genome. Notably, these observations highlight an interesting perspective of 304 polygenic effects, in so much as it provides support for a mixture of effects on tobacco 305
consumption. 306
This study demonstrates the importance of transcriptionally regulated genes and is in 307 accordance with broad human GWAS research, which detects most of its associations among 308 intergenic regions. 1 Our results suggest that the genetic proclivity to tobacco use is mediated, in 309 part, by gene expression in relevant brain regions that relate to specific behavioral mechanisms. 310
Similarly recent genome-wide research identified genome-wide significant loci in 311 neurotransmission and reward learning genes for tobacco use and prioritized non-synonymous 312 protein coding variants. 6 By using just half of the sample size from Liu et al., our findings 313 corroborated the importance of reward-related and neurotransmission genes and further 314 disentangle the underlying genetic structure of tobacco consumption by highlighting 315 transcriptionally relevant cis-eQTLs in hundreds of genomic regions. Overall, our study suggests 316 that the genetic architecture of tobacco consumption feeds into the neuro-molecular landscape 317 via modulation of gene expression. 318
These data also suggest that the use of model systems allows for the direct sampling of 319 brain tissue, in the context of a trait relevant phenotype which models, in a simplified way, characteristics of human disease measured in an organism (e.g., Mus musculus, Drosophilae 321
Melanogaster, Rattus Norvegicus, and Caenorhabditis elegans, to name a few) with a genome 322 that has some similarities to humans, including mammals with high percentages of orthologous 323 genes. It is important to note that when we refer to "modeling" here, we are not referring to the 324 questionable practice of establishing a single gene perturbation in a model organism as a 325 "model" of a person with a disease. Rather we are referring to the practice of evaluating the 326 complex genomic basis of traits that are characteristic of various aspects of the disease state. 327 Taken alone, model system work has a number of key advantages (over and above access to 328 brain tissue) including, but not limited to, the use of neurogenetic methods (e.g., optogenetic, 329 thermogenetic, etc.) which can introduce much larger biological effects in model systems than 330 could be seen in typical GWAS studies. Additionally, controlled environmental exposures (e.g., 331 pharmacological, behavioral, etc.) may be used in model systems in a fashion that would be 332 impossible in humans. The strengths of model systems allow for smaller-sample studies to be 333 maximally informative due to larger effect sizes and tighter experimental control, but the 334 "translatability" of these findings to the human condition has limitations. While some more 335 basic behavioral traits are convincingly modeled in animals, other complex phenotypes and 336 disorders are represented only in part by these systems 29 . Furthermore, the phylogenetic 337 distance between the model organism and Homo sapiens can pose additional challenges as only a 338 subset of genes will be conserved in an informative way; notably, studies have shown 339 conservation of epigenetic marks across mice and humans. 30 Attempts to leverage conserved 340 evidence across mice and humans in alcohol dependence research have revealed networks of 341 genes and loci, which had gone undetected in prior GWAS. 31 In sum, model systems bring unique advantages and disadvantages to behavior genetics that may complement human GWAS 343 studies of related traits. 344
These analyses identified various genes previously linked to nicotine consumption and 345 cessation, including validated nicotinic acetylcholine receptor genes CHRNA3/A4/A5/B4, as well 346 as nicotine metabolism genes (CYP2A6/A7), which provides a sanity-check for our genome-wide 347 analyses. Mechanistic research in mice suggests that a mutation of the CHRNA5 gene and 348 concomitant habenular expression of CHRNA5 robustly increases nicotine consumption, but not 349 after experimentally restoring habenuala CHRNA5 levels back to normal 32 . These results buttress 350 our findings delineating the path from genetic predisposition to gene expression and eventually 351 specific behavioral outcomes and may suggest a gene x drug interaction. That is, those at higher 352 genetic risk for tobacco use may have an altered physiological response that increases 353 susceptibility for augmented consumption. 33; 34 Apart from the established nicotinic acetylcholine 354 receptors, we also discovered significant genetic association of chromosome 19 genes: RAB4B, 355 EGLN2 and CYP2A6 with tobacco consumption. RAB4B is involved in the breakdown of GTP 356 for vesicular transport 35 and was previously associated with PFC gene expression among those 357 with major depression. 36 While RAB4B, EGLN2 and CYP2A6 are in strong linkage 358 disequilibrium, research suggests they correspond to largely independent mechanisms. 37 Our 359 study suggests that RAB4B is driven by a brain-dependent mechanism (identified in mice) 38 and 360 might underlie neuroplasticity processes related to nicotine reward 39 . On the other hand, EGLN2 361 and CYP2A6 were not associated with gene expression findings in animal models of nicotine 362 use/exposure. EGLN2 is a hypoxia inducible factor and plays a role in oxygen homeostasis 40 and 363 may be uniquely associated with humans because the vehicle for nicotine intake is via oxygen 364 restricting smoke (i.e., carbon monoxide present in cigarette smoke preferentially binds to hemoglobin and thus reduces its ability to transport oxygen), whereas animal models typically 366 study nicotine through injections or implementation in the drinking water. CYP2A6 is an enzyme 367 that accounts for ~80% of nicotine clearance 41 and is almost exclusively expressed in the liver, 368 which is a likely reason that it was not included in our brain-mediated cross-species gene list. 369 Therefore, our integrative approach better contextualizes the effects of genes associated with 370 human complex traits and better determines how specific genetic associations relate to relevant 371 model systems in particular tissues. 372
While novel, there are several considerations for interpreting the current findings. First, 373 these analyses are limited by current understanding of the consequences of tobacco exposure 374 using only microarray studies. We sought to overcome this limitation by integrating multiple 375 sources of information using differences across brain and model organisms, but future studies are 376 needed to determine whether these effects are invariant, as well as whether the experimental 377 paradigm itself may alter this line of evidence, especially as the volume of literature increases. 378
Second, our analyses did not examine genes that have been shown to be differentially methylated 379 by tobacco exposure; we assumed that such processes would equate to direct differences in 380 mRNA levels, constructed gene list utilized animal research, which focused primarily on 381 orthologous genes. 42; 43 As such, there was less emphasis on regulatory elements for said genes, 382 which may also generalize across species. We attempted to capture said effects by using buffers 383 of various lengths to approximate the relative import of cis and possibly trans acting effects. It 384 should be noted however, that our results are in line with the multiple enhancer variant 385 hypothesis, which purports a similar role of noncoding variants in common traits. 44 386 Future research is warranted to determine whether our integrative framework generalizes 387 across complex human traits. Traits with different genetic architectures, epigenetic landscapes and animal models may yield disparate findings. We found that the bulk of our cross-species 389 signal stemmed from mouse models of nicotine use, but it will be important for future research to 390 be conducted across multiple smoking phenotypes and include additional species/studies and 391 incorporate findings from human tissues to benchmark findings with other model organisms. 392
Ideally, integrative genomics comparisons would leverage equitable and minimally error prone 393 outcomes or endophenotypes across studies. Given the array of animal models for human traits, 394
an inviting avenue of research should clarify the utility of specific tissues, cell types and animal 395 models in human genetics. With a large enough literature base, we may be able to better refine 396 what tissues and specific mechanisms human genomic signals stem from and ultimately may 397 better characterize the genetic make-up for complex traits. Future studies leveraging these 398 approaches should consider strategies for reducing buffer size and examining heterogeneity 399 across tissue/cell types, as well as whether the observed effects generalize across human 400 populations (e.g., European, African, Asian, etc). 401 402
Conclusions 403
In sum, this study represents a step forward for interspecies behavioral genetics and 404 provides a proof of principle for bridging the gap between human and animal genetics in 405 identifying polygenic risk variants. We show that enhancing human GWAS by incorporating a 406 priori information on relevant traits (even across species) is a worthwhile path to unraveling the 407 genetic basis for complex traits. 408 e  t  i  c  d  e  t  e  r  m  i  n  a  n  t  s  a  n  d  m  e  c  h  a  n  i  s  m  s  o  f  a  d  d  i  c  t  i  o  n  t  o   501   n  i  c  o  t  i  n  e  a  n  d  s  m  o  k  e  d  t  o  b  a  c  c  o  .  E  u  r  o  p  e  a  n  J  o  u  r  n  a  l  o  f  N  e  u  r  o  s  c  i  e  n  c  e  5  0  ,  2  1  6  4  -2  1  7  9  .   502   3  5  .  H  e  ,  H  .  ,  D  a  i  ,  F  .  ,  Y  u  ,  L  .  ,  S  h  e  ,  X  .  ,  Z  h  a  o  ,  Y  .  ,  J  i  a  n  g  ,  J  .  ,  C  h  e  n  ,  X  .  ,  a  n  d  Z  h  a  o  ,  S  .  (  2  0  0  2  )  .  I  d  e  n  t  i  f  i  c  a  t  i  o  n  a  n  d   503   c  h  a  r  a  c  t  e  r  i  z  a  t  i  o  n  o  f  n  i  n  e  n  o  v  e  l  h  u  m  a  n  s  m  a  l  l  G  T  P  a  s  e  s  s  h  o  w  i  n  g  v  a  r  i  a  b  l  e  e  x  p  r  e  s  s  i  o  n  s  i  n  l  i  v  e  r  c  a  n  c  e 
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